Skip to Content
Merck
CN

Dystonia and parkinsonism in GM1 type 3 gangliosidosis.

Movement disorders : official journal of the Movement Disorder Society (2005-06-30)
Emmanuel Roze, Eduard Paschke, Nathalie Lopez, Thomas Eck, Kunihiro Yoshida, Annie Maurel-Ollivier, Diane Doummar, Catherine Caillaud, Damien Galanaud, Thierry Billette de Villemeur, Marie Vidailhet, Anne Roubergue
ABSTRACT

GM1 gangliosidosis is due to beta-galactosidase deficiency. Only patients with type 3 disease survive into adulthood and develop movement disorders. Clinical descriptions of this form are rare, particularly in non-Japanese patients. We describe four new patients and systematically analyze all previous reports found by a literature search and contacts with the authors for additional information. Generalized dystonia remained the predominant feature throughout the disease course and was often associated with akinetic-rigid parkinsonism. GM1 gangliosidosis must be considered as a cause of early-onset generalized dystonia, particularly in patients with short stature and skeletal dysplasia.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
β-Galactosidase from Escherichia coli, suitable for enzyme immunoassay, lyophilized, powder, ~140 U/mg
Sigma-Aldrich
β-Galactosidase from Escherichia coli, aqueous glycerol suspension, ≥500 units/mg protein (biuret)
Sigma-Aldrich
β-Galactosidase from Escherichia coli, Grade VIII, lyophilized powder, ≥500 units/mg protein
Sigma-Aldrich
β-Galactosidase from Escherichia coli, Grade VI, lyophilized powder, ≥250 units/mg protein
Sigma-Aldrich
β-Galactosidase from bovine testes, ammonium sulfate suspension, 1.0-3.0 units/mg protein (modified Warburg-Christian)
Sigma-Aldrich
β-Galactosidase from Escherichia coli, lyophilized powder, ≥500 units/mg protein
Sigma-Aldrich
β-Galactosidase from bovine liver, Grade III, lyophilized powder, ≥0.15 units/mg protein
Sigma-Aldrich
β-Galactosidase from Aspergillus oryzae, ≥8.0 units/mg solid